Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 May-Jun;18(3):1004-1014.
doi: 10.1016/j.brs.2025.04.018. Epub 2025 Apr 29.

Deep transcranial ultrasound stimulation using personalized acoustic metamaterials improves treatment-resistant depression in humans

Affiliations
Free article
Clinical Trial

Deep transcranial ultrasound stimulation using personalized acoustic metamaterials improves treatment-resistant depression in humans

David Attali et al. Brain Stimul. 2025 May-Jun.
Free article

Abstract

Background: Neuromodulation of deep brain regions has shown promise for treatment-resistant depression (TRD). However, it currently requires neurosurgical electrode implantation, posing significant risks and limiting widespread use while TRD affects around 100 million people worldwide. Low-intensity transcranial ultrasound stimulation (TUS) could allow precise and non-invasive deep neuromodulation, provided that the challenge of the defocusing effects of the skull is tackled.

Objective/hypothesis: Here, we present the development of a portable and neuronavigated TUS prototype based on the use of patient-specific metamaterials (metalens) that correct for skull-induced aberrations. We then present the first application of metalens-based Transcranial Ultrasound Stimulation (mTUS) in TRD. The primary objective was to assess the safety and efficacy of mTUS targeting on individual level specific white matter tracts of the subcallosal cingulate involved in TRD.

Methods: The safety and precision of this device was addressed through a series of numerical simulations and experimental measurements on ex vivo human skulls. Five participants with TRD were included in this open-label study (ClinicalTrials.gov identifier: NCT06085950) and underwent an intensive 5-day course of mTUS with a total of 25 sessions of 5 min each.

Results: No serious adverse events occurred during the study. By day 5 of treatment, depression severity was reduced by an average of 60.9 % (range: [30 %-83.9 %]), and four out of five patients qualified as responders, with two of them in remission.

Conclusions: This study provides first-in-human evidence of the potential of mTUS as a precise, safe and effective non-invasive neuromodulation technique for neuropsychiatric disorders involving deep brain regions, offering a safer and more accessible alternative to invasive approaches.

Keywords: Focused ultrasound neuromodulation; Personalized acoustic metalens; Subcallosal cingulate; Tractography; Transcranial ultrasound stimulation; Treatment-resistant depression.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest MP has been invited to scientific meetings, consulted and served as a speaker, and received compensation from Janssen. TT, JFA and MT hold patents related to the technology described in this study. After the study was completed, TT, JFA and MT co-founded SonoMind, a startup company related to the technology described in this study and hold shares. After the study was completed, TJM became a consultant for Nudge, a company developing transcranial ultrasound stimulation. The remaining authors declare no competing interests and no financial relationships with commercial interests.

Publication types

Associated data

LinkOut - more resources